The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma
This study aimed to assess the benefit of postoperative adjuvant chemotherapy in stage II–III colorectal signet ring cell carcinoma (SRCC). Qualified postoperative patients were extracted from Surveillance, Epidemiology, and End Results (SEER) database from 2004 until 2015. We collected 1675 patient...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2020-08, Vol.10 (1), p.14126-14126, Article 14126 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14126 |
|---|---|
| container_issue | 1 |
| container_start_page | 14126 |
| container_title | Scientific reports |
| container_volume | 10 |
| creator | Zhao, Zhuang Yan, Na Pan, Shu Wang, Dun-wei Li, Zhi-wen |
| description | This study aimed to assess the benefit of postoperative adjuvant chemotherapy in stage II–III colorectal signet ring cell carcinoma (SRCC). Qualified postoperative patients were extracted from Surveillance, Epidemiology, and End Results (SEER) database from 2004 until 2015. We collected 1675 patients in the research, and 936 patients were subjected to adjuvant chemotherapy group. The proportions of married status, male, rectal cancer, grade III/IV, AJCC stage III and radiotherapy were higher; While, the rates of white race, ≥ 65 years old and located in cecum–transverse colon were lower in patients of chemotherapy group compared to no chemotherapy group (all
P
|
| doi_str_mv | 10.1038/s41598-020-70985-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7445263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2436698240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-a3217b28ae9ab340ca40bdc25c3df12238c749c2b6c48b18431815305edad5cb3</originalsourceid><addsrcrecordid>eNp9kUFP3DAQha0KVBDlD3BAlrhwSbHH9sa-IFUI2khIvYDEzZo43t2sEnuxk5X49yRdSmkP9WUs-Zs3fvMIOePsK2dCX2XJldEFA1aUzGhVsE_kGJhUBQiAgw_3I3Ka84ZNR4GR3HwmRwK0MAr0MXl6WHu6w270NC4pNptxh2Ggbu37OKx9wu0LbQPNA648raqrqqqoi11M3g3Y0dyugh9oasOKOt911GFybYg9fiGHS-yyP32rJ-Tx7vbh5kdx__N7dfPtvnCylEOBAnhZg0ZvsBaSOZSsbhwoJ5olBxDaldI4qBdO6pprKbjmSjDlG2yUq8UJud7rbse6943zYUjY2W1qe0wvNmJr_34J7dqu4s6WUipYiEng8k0gxefR58H2bZ69YPBxzBakKDlwMHpCL_5BN3FMYbI3U4uF0SDZRMGecinmnPzy_TOc2Tk7u8_OTtnZX9nZuen8o433lt9JTYDYA3k7b9unP7P_I_sKaiykiA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2436698240</pqid></control><display><type>article</type><title>The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Zhao, Zhuang ; Yan, Na ; Pan, Shu ; Wang, Dun-wei ; Li, Zhi-wen</creator><creatorcontrib>Zhao, Zhuang ; Yan, Na ; Pan, Shu ; Wang, Dun-wei ; Li, Zhi-wen</creatorcontrib><description>This study aimed to assess the benefit of postoperative adjuvant chemotherapy in stage II–III colorectal signet ring cell carcinoma (SRCC). Qualified postoperative patients were extracted from Surveillance, Epidemiology, and End Results (SEER) database from 2004 until 2015. We collected 1675 patients in the research, and 936 patients were subjected to adjuvant chemotherapy group. The proportions of married status, male, rectal cancer, grade III/IV, AJCC stage III and radiotherapy were higher; While, the rates of white race, ≥ 65 years old and located in cecum–transverse colon were lower in patients of chemotherapy group compared to no chemotherapy group (all
P
< 0.05). K-M plots revealed significantly better OS of adjuvant chemotherapy group than no chemotherapy group (
P
< 0.001). Meanwhile, there was no significantly different in CSS between the two groups (
P
= 0.93). However, after adjusting for confounding factors by multivariable Cox regression analysis, receipt of postoperative chemotherapy was still associated with better CSS and OS (CSS: hazard ratio [HR] = 0.719, 95% CI 0.612–0.844,
P
< 0.001) ; (OS: HR = 0.618, 95% CI 0.537–0.713,
P
< 0.001). Patients with stage II/III colorectal SRCC could receive survival benefit from postoperative adjuvant chemotherapy.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-70985-0</identifier><identifier>PMID: 32839528</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67 ; 692/4028 ; 692/499 ; Aged ; Carcinoma, Signet Ring Cell - drug therapy ; Carcinoma, Signet Ring Cell - mortality ; Carcinoma, Signet Ring Cell - pathology ; Cecum ; Cecum - pathology ; Chemotherapy ; Chemotherapy, Adjuvant - methods ; Colon ; Colon, Transverse - pathology ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Databases, Factual ; Epidemiology ; Female ; Humanities and Social Sciences ; Humans ; Male ; multidisciplinary ; Neoplasm Staging ; Postoperative Period ; Prognosis ; Radiation therapy ; Rectum ; Regression analysis ; Science ; Science (multidisciplinary) ; SEER Program ; Survival Analysis</subject><ispartof>Scientific reports, 2020-08, Vol.10 (1), p.14126-14126, Article 14126</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-a3217b28ae9ab340ca40bdc25c3df12238c749c2b6c48b18431815305edad5cb3</citedby><cites>FETCH-LOGICAL-c474t-a3217b28ae9ab340ca40bdc25c3df12238c749c2b6c48b18431815305edad5cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445263/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445263/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,41119,42188,51575,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32839528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Zhuang</creatorcontrib><creatorcontrib>Yan, Na</creatorcontrib><creatorcontrib>Pan, Shu</creatorcontrib><creatorcontrib>Wang, Dun-wei</creatorcontrib><creatorcontrib>Li, Zhi-wen</creatorcontrib><title>The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>This study aimed to assess the benefit of postoperative adjuvant chemotherapy in stage II–III colorectal signet ring cell carcinoma (SRCC). Qualified postoperative patients were extracted from Surveillance, Epidemiology, and End Results (SEER) database from 2004 until 2015. We collected 1675 patients in the research, and 936 patients were subjected to adjuvant chemotherapy group. The proportions of married status, male, rectal cancer, grade III/IV, AJCC stage III and radiotherapy were higher; While, the rates of white race, ≥ 65 years old and located in cecum–transverse colon were lower in patients of chemotherapy group compared to no chemotherapy group (all
P
< 0.05). K-M plots revealed significantly better OS of adjuvant chemotherapy group than no chemotherapy group (
P
< 0.001). Meanwhile, there was no significantly different in CSS between the two groups (
P
= 0.93). However, after adjusting for confounding factors by multivariable Cox regression analysis, receipt of postoperative chemotherapy was still associated with better CSS and OS (CSS: hazard ratio [HR] = 0.719, 95% CI 0.612–0.844,
P
< 0.001) ; (OS: HR = 0.618, 95% CI 0.537–0.713,
P
< 0.001). Patients with stage II/III colorectal SRCC could receive survival benefit from postoperative adjuvant chemotherapy.</description><subject>631/67</subject><subject>692/4028</subject><subject>692/499</subject><subject>Aged</subject><subject>Carcinoma, Signet Ring Cell - drug therapy</subject><subject>Carcinoma, Signet Ring Cell - mortality</subject><subject>Carcinoma, Signet Ring Cell - pathology</subject><subject>Cecum</subject><subject>Cecum - pathology</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>Colon</subject><subject>Colon, Transverse - pathology</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Databases, Factual</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Male</subject><subject>multidisciplinary</subject><subject>Neoplasm Staging</subject><subject>Postoperative Period</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Rectum</subject><subject>Regression analysis</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>SEER Program</subject><subject>Survival Analysis</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kUFP3DAQha0KVBDlD3BAlrhwSbHH9sa-IFUI2khIvYDEzZo43t2sEnuxk5X49yRdSmkP9WUs-Zs3fvMIOePsK2dCX2XJldEFA1aUzGhVsE_kGJhUBQiAgw_3I3Ka84ZNR4GR3HwmRwK0MAr0MXl6WHu6w270NC4pNptxh2Ggbu37OKx9wu0LbQPNA648raqrqqqoi11M3g3Y0dyugh9oasOKOt911GFybYg9fiGHS-yyP32rJ-Tx7vbh5kdx__N7dfPtvnCylEOBAnhZg0ZvsBaSOZSsbhwoJ5olBxDaldI4qBdO6pprKbjmSjDlG2yUq8UJud7rbse6943zYUjY2W1qe0wvNmJr_34J7dqu4s6WUipYiEng8k0gxefR58H2bZ69YPBxzBakKDlwMHpCL_5BN3FMYbI3U4uF0SDZRMGecinmnPzy_TOc2Tk7u8_OTtnZX9nZuen8o433lt9JTYDYA3k7b9unP7P_I_sKaiykiA</recordid><startdate>20200824</startdate><enddate>20200824</enddate><creator>Zhao, Zhuang</creator><creator>Yan, Na</creator><creator>Pan, Shu</creator><creator>Wang, Dun-wei</creator><creator>Li, Zhi-wen</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200824</creationdate><title>The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma</title><author>Zhao, Zhuang ; Yan, Na ; Pan, Shu ; Wang, Dun-wei ; Li, Zhi-wen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-a3217b28ae9ab340ca40bdc25c3df12238c749c2b6c48b18431815305edad5cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/67</topic><topic>692/4028</topic><topic>692/499</topic><topic>Aged</topic><topic>Carcinoma, Signet Ring Cell - drug therapy</topic><topic>Carcinoma, Signet Ring Cell - mortality</topic><topic>Carcinoma, Signet Ring Cell - pathology</topic><topic>Cecum</topic><topic>Cecum - pathology</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>Colon</topic><topic>Colon, Transverse - pathology</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Databases, Factual</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Male</topic><topic>multidisciplinary</topic><topic>Neoplasm Staging</topic><topic>Postoperative Period</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Rectum</topic><topic>Regression analysis</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>SEER Program</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Zhuang</creatorcontrib><creatorcontrib>Yan, Na</creatorcontrib><creatorcontrib>Pan, Shu</creatorcontrib><creatorcontrib>Wang, Dun-wei</creatorcontrib><creatorcontrib>Li, Zhi-wen</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Zhuang</au><au>Yan, Na</au><au>Pan, Shu</au><au>Wang, Dun-wei</au><au>Li, Zhi-wen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-08-24</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>14126</spage><epage>14126</epage><pages>14126-14126</pages><artnum>14126</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>This study aimed to assess the benefit of postoperative adjuvant chemotherapy in stage II–III colorectal signet ring cell carcinoma (SRCC). Qualified postoperative patients were extracted from Surveillance, Epidemiology, and End Results (SEER) database from 2004 until 2015. We collected 1675 patients in the research, and 936 patients were subjected to adjuvant chemotherapy group. The proportions of married status, male, rectal cancer, grade III/IV, AJCC stage III and radiotherapy were higher; While, the rates of white race, ≥ 65 years old and located in cecum–transverse colon were lower in patients of chemotherapy group compared to no chemotherapy group (all
P
< 0.05). K-M plots revealed significantly better OS of adjuvant chemotherapy group than no chemotherapy group (
P
< 0.001). Meanwhile, there was no significantly different in CSS between the two groups (
P
= 0.93). However, after adjusting for confounding factors by multivariable Cox regression analysis, receipt of postoperative chemotherapy was still associated with better CSS and OS (CSS: hazard ratio [HR] = 0.719, 95% CI 0.612–0.844,
P
< 0.001) ; (OS: HR = 0.618, 95% CI 0.537–0.713,
P
< 0.001). Patients with stage II/III colorectal SRCC could receive survival benefit from postoperative adjuvant chemotherapy.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32839528</pmid><doi>10.1038/s41598-020-70985-0</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2020-08, Vol.10 (1), p.14126-14126, Article 14126 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7445263 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | 631/67 692/4028 692/499 Aged Carcinoma, Signet Ring Cell - drug therapy Carcinoma, Signet Ring Cell - mortality Carcinoma, Signet Ring Cell - pathology Cecum Cecum - pathology Chemotherapy Chemotherapy, Adjuvant - methods Colon Colon, Transverse - pathology Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Databases, Factual Epidemiology Female Humanities and Social Sciences Humans Male multidisciplinary Neoplasm Staging Postoperative Period Prognosis Radiation therapy Rectum Regression analysis Science Science (multidisciplinary) SEER Program Survival Analysis |
| title | The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T21%3A22%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20value%20of%20adjuvant%20chemotherapy%20in%20stage%20II/III%20colorectal%20signet%20ring%20cell%20carcinoma&rft.jtitle=Scientific%20reports&rft.au=Zhao,%20Zhuang&rft.date=2020-08-24&rft.volume=10&rft.issue=1&rft.spage=14126&rft.epage=14126&rft.pages=14126-14126&rft.artnum=14126&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-70985-0&rft_dat=%3Cproquest_pubme%3E2436698240%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2436698240&rft_id=info:pmid/32839528&rfr_iscdi=true |